1. "Hematologic Malignancies Service"
Formats
  1. Journal Article (349)
  2. Meeting Abstract (232)
  3. Review (11)
  4. Research Letter (5)
  5. Editorial (4)
  6. Book Section (2)
  7. Conference Paper (2)
  8. Correspondence (1)
  9. Guidelines (1)
Groups
  1. Hematologic Malignancies Service (607)
  2. Pediatrics, Department of (607)
  3. Center for Hematologic Malignancies (554)
  4. Pediatric Leukemia (455)
  5. GSK Faculty (220)
  6. Tow Center for Developmental Oncology (TCDO) (206)

More Groups

People
  1. Peter Steinherz (221)
  2. Neerav Shukla (159)
  3. Tanya Trippett (126)
  4. Alex Kentsis (103)
  5. Christopher Forlenza (49)
  6. Marc Ladanyi (44)

More People

Years
  1. 2025 (11)
  2. 2024 (27)
  3. 2023 (37)
  4. 2022 (34)
  5. 2021 (29)
  6. 2020 (29)

More Years

Publications
  1. Blood (125)
  2. Journal of Clinical Oncology (61)
  3. Pediatric Blood and Cancer (57)
  4. Cancer Research (22)
  5. Cancer (18)
  6. Journal of Pediatric Hematology/Oncology (16)

More Publications

Publishers
  1. American Society of Hematology (134)
  2. American Society of Clinical Oncology (69)
  3. Wiley Periodicals, Inc (57)
  4. American Association for Cancer Research (56)
  5. Nature Publishing Group (39)
  6. Elsevier Inc. (33)

More Publishers

Results (607)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemias: Efficacy and safety results from the AUGMENT-101 phase 1/2 study
    Meeting Abstract

    Aldoss, I.; Issa, G. C.; Thirman, M. J.; DiPersio, J.; Arellano, M.; Blachly, J. S.; Mannis, G.; Perl, A.; Dickens, D.; McMahon, C. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A de novo supernumerary ring chromosome 1 causes B-cell acute lymphoblastic leukemia in monozygotic twins due to independent and partially convergent evolutionary trajectories
    Meeting Abstract

    GutieĢrrez-Abril, J.; Gundem, G.; Fiala, E.; Liosis, K.; Farnoud, N.; Leongamornlert, D.; Amallraja, A.; Ossa, J. E. A.; Domenico, D.; Levine, M. F.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Results from an intergroup randomized phase II study of the combinations of ipilimumab, nivolumab and brentuximab vedotin in patients with relapsed/refractory classic Hodgkin lymphoma: A trial of the ECOG-ACRIN Research Group (E4412)
    Meeting Abstract

    Diefenbach, C. S.; Jegede, O.; Ansell, S. M.; Steidl, C.; Natkunam, Y.; Scott, D. W.; Mehta-Shah, N.; Amengual, J. E.; Forlenza, C. J.; Cole, P. D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Progression-free survival (PFS) and toxicity with nivolumab-AVD compared to brentuximab vedotin-AVD in pediatric advanced stage (AS) classic Hodgkin lymphoma (cHL), results of SWOG S1826
    Meeting Abstract

    Castellino, S. M.; Li, H.; Herrera, A. F.; Punnett, A.; Leblanc, M.; Parsons, S. K.; Hodgson, D.; Keller, F.; Drachtman, R. A.; Lamble, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy of venetoclax and selinexor in combination with chemotherapy in pediatric and young adult patients with relapsed or refractory acute myeloid leukemia: SELCLAX
    Meeting Abstract

    Zarnegar-Lumley, S.; Karol, S. E.; Pounds, S.; Klco, J. M.; Sulis, M. L.; Kuo, D. J.; Heym, K. M.; Ludwig, K.; Stevens, A. M.; Alexander, T. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Pembrolizumab (pembro) in children and young adults with low-risk classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo): Early results from the phase 2 KEYNOTE-667 study
    Meeting Abstract

    Roth, L. G.; Keller, F.; Toledo, M. M.; Castellino, S. M.; Forlenza, C. J.; Catalan, M. A.; Krystal, J.; Lamble, A.; Rao, A. V.; Morales, F. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemia: Topline efficacy and safety results from the pivotal Augment-101 phase 2 study
    Meeting Abstract

    Aldoss, I.; Issa, G. C.; Thirman, M.; DiPersio, J.; Arellano, M.; Blachly, J. S.; Mannis, G. N.; Perl, A.; Dickens, D. S.; McMahon, C. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical targeted next-generation panel sequencing reveals MYC amplification is a poor prognostic factor in osteosarcoma
    Journal Article

    Marinoff, A. E.; Spurr, L. F.; Fong, C.; Li, Y. Y.; Forrest, S. J.; Ward, A.; Doan, D.; Corson, L.; Mauguen, A.; Pinto, N.; more...
    JCO Precision Oncology (2023)

    Fulltext@MSK | Save
  • Epigenetic cooperativity as a therapeutic vulnerability in cancer
    Editorial

    Kazansky, Y.; Kentsis, A.
    Cancer Research (2023)

    Fulltext@MSK | Save
  • EZH2 inhibition: It's all about the context
    Editorial

    Rosen, E. Y.; Shukla, N. N.; Glade Bender, J. L.
    JNCI: Journal of the National Cancer Institute (2023)

    Fulltext@MSK | Save